The stability of this product in solution has not been determined. However, various sources report that stock solution are stable for up to 3 months when stored in aliquots at -20°C. This information has not been validated.
A6733
Auranofin
≥98% (HPLC), powder, leukocyte activation pathway inhibitor
동의어(들):
1-Thio-β-D-glucopyranosatotriethylphosphine gold-2,3,4,6-tetraacetate, 3,4,5-Triacetyloxy-6-(acetyloxymethyl) oxane-2-thiolate triethylphosphanium, SKF 39162
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
| 여러분께/SKU | 재고 정보 | 가격 (VAT 별도) |
|---|---|---|
10 mg | 오늘 배송 가능재고 수량 조회Seoul Warehouse South Korea | ₩243,296 |
50 mg | 구입 가능 여부는 고객센터에 문의하십시오. | ₩963,540 |
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C20H34AuO9PS
CAS 번호:
Molecular Weight:
678.48
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
EC Number:
251-801-9
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
제품 이름
Auranofin, ≥98% (HPLC)
Quality Segment
assay
≥98% (HPLC)
form
powder
solubility
DMSO: ≥5 mg/mL
originator
Prometheus
storage temp.
room temp
SMILES string
CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O
InChI
1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1/t10-,11-,12+,13-,14+;;/m1../s1
InChI key
AUJRCFUBUPVWSZ-XTZHGVARSA-M
Application
Auranofin inhibits both leukocyte activation pathways at multiple sites and the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. Auranofin also inhibits 5-lipoxygenase in human neutrophils, IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5 and selenoenzyme thioredoxin reductase (TrxR) which is involved in the defense against oxidative stress. Auranofin is a disease-modifying antirheumatic drug (DMARD) and has been used to study the anti-proliferative effects against OVCAR-3 human ovarian carcinoma cells.
Biochem/physiol Actions
Auranofin inhibits various leukocyte activation pathways at multiple sites and is a disease-modifying antirheumatic drug (DMARD).
Auranofin inhibits various leukocyte activation pathways at multiple sites. Auranofin inhibits the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. The compound also inhibits 5-lipoxygenase in human neutrophils. Auranofin is a disease-modifying antirheumatic drug (DMARD). The compound is a potent inhibitor of selenoenzyme thioredoxin reductase (TrxR), which is involved in defense against oxidative stress. Auranofin is an efficient inducer of mitochondrial membrane permeability transition pore in the presence of calcium ions related to its inhibition of mitochondrial thioredoxin reductase. Auranofin inhibits IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5.
Features and Benefits
This compound was developed by Prometheus. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
1 of 1
이 품목 | |||
|---|---|---|---|
| form powder | form powder | form powder | form powder |
| assay ≥98% (HPLC) | assay ≥95% (HPLC) | assay ≥97% (HPLC) | assay ≥98% (HPLC) |
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 100 |
| storage temp. room temp | storage temp. room temp | storage temp. −20°C | storage temp. room temp |
| solubility DMSO: ≥5 mg/mL | solubility DMSO: 5 mg/mL, clear (warmed) | solubility DMSO: 5 mg/mL, clear (warmed) | solubility DMSO: 5 mg/mL, clear (warmed) |
| originator Prometheus | originator - | originator - | originator - |
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Repr. 2
저장 등급
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves